Cite
HARVARD Citation
Müller‐Tidow, C. et al. (n.d.). A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the Polo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. British journal of haematology. pp. 214-222. [Online].